Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269305 | PMC |
| http://dx.doi.org/10.3324/haematol.2018.196782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
J Clin Oncol
September 2020
Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY.
Purpose: Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)-directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.
View Article and Find Full Text PDFSOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk
February 2018
Washington University School of Medicine, St. Louis, MO. Electronic address:
Until recently, advances in classic Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early-stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses, smaller radiation fields and in some circumstances, radiation elimination. In advanced-stage disease, maintaining the dose intensity of standard chemotherapy regimens has resulted in modest improvements in outcomes.
View Article and Find Full Text PDFFrontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.
Clin Med Insights Oncol
September 2017
Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA, USA.
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!